Y. Yamaguchi

Efficacy and Safety of Oral Ritlecitinib for the Treatment of Active Nonsegmental Vitiligo: A Randomized Phase 2b Clinical Trial.

A. Ganesan, M. Picardo, E. Peeva, 2022, Journal of the American Academy of Dermatology.

Prevalence of Vitiligo among Children and Adolescents in the United States

V. Sikirica, K. Ezzedine, A. Pandya, 2023, Dermatology.

Role of Innate Immunity in Allergic Contact Dermatitis: An Update

E. Peeva, Y. Yamaguchi, Hiroki L. Yamaguchi, 2023, International journal of molecular sciences.

Impact of nonsegmental vitiligo on patients’ health‐related quality of life in the United States

V. Sikirica, K. Ezzedine, A. Pandya, 2022, The British journal of dermatology.

Prevalence of Vitiligo Among Adults in the United States

V. Sikirica, K. Ezzedine, A. Pandya, 2021, JAMA dermatology.

Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo

Zhan Ye, E. Guttman‐Yassky, P. Facheris, 2024, Archives of dermatological research.

Hair regrowth in alopecia areata and re-pigmentation in vitiligo in response to treatment: Commonalities and differences.

Y. Yamaguchi, E. Peeva, Hiroki L Yamaguchi, 2024, Journal of the European Academy of Dermatology and Venereology : JEADV.